Corvus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders held by Corvus Pharmaceuticals, Inc. on June 9, 2020. The record date for the meeting was April 13, 2020, with 27,953,233 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
Two proposals were presented to stockholders, with 24,166,491 shares voted in person or by proxy:
- Proposal No. 1 (Election of Directors): Stockholders elected Class III director nominees Richard A. Miller, M.D., and Linda S. Grais, M.D., J.D., to serve until the 2023 Annual Meeting.
- Richard A. Miller, M.D.: 20,522,672 votes For; 73,472 votes Withheld; 3,570,347 Broker Non-Votes.
- Linda S. Grais, M.D., J.D.: 20,503,321 votes For; 92,823 votes Withheld; 3,570,347 Broker Non-Votes.
- Proposal No. 2 (Ratification of Accounting Firm): Stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Votes: 24,158,965 For; 3,559 Against; 3,967 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that PricewaterhouseCoopers LLC is the appointed auditor for the fiscal year ending December 31, 2020.
- Verification of the new Board of Directors composition following the election of Class III nominees.
- Review of the Definitive Proxy Statement on Schedule 14A (filed April 15, 2020) for detailed background on the proposals.